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Aurora A is amitotic kinase that is essential for regulation of the G2/M checkpoint. In this issue ofCancer Cell,
Otto et al. report that Aurora A interacts with MYCN, a potent oncogene in human neuroblastoma, and
sequesters it from proteolytic degradation. This surprising finding further enhances Aurora A’s potential as
a therapeutic target.The Aurora kinases have attracted intense
scrutiny in recent years due to accumu-
lating evidence that they often act as
oncogenic drivers in many human cancers
(Gautschi et al., 2008). The Aurora family
consists of three known gene paralogs
(AURKA, AURKB, and AURKC) that are
key regulators of mitosis. The genes
each encode serine/threonine kinases
with a significant degree of homology in
the C-terminal catalytic domain, suggest-
ing that the divergent N-terminal domains
distinguish their diverse effects on the cell
cycle and mitosis. While little is known
about Aurora C, and Aurora B appears to
play a regulatory role throughout mitosis,
recent evidence strongly suggests that
Aurora A has a more restricted role in the
cell cycle and is absolutely required for
the G2/M transition via phosphorylation
of polo-like kinase 1 in concert with the
cofactor Bora (Macurek et al., 2008; Sasai
et al., 2008). In addition, Aurora A is critical
for mitotic spindle assembly and stability,
as well as regulation of centrosomal and
kinetochore formation (Marumoto et al.,
2005). It is therefore not surprising that
Aurora A expression is tightly regulated
throughout normal development and the
cell cycle and that engineered Aurkadeficiency in mice is early embryonic
lethal (Sasai et al., 2008). Finally, AURKA
amplification/overexpression iscommonly
seen in a variety of human neoplasms,
and there has been interest in leveraging
this fact therapeutically (Gautschi et al.,
2008).
Likewise, the Myc family of transcription
factors is commonly deregulated in
cancer, via chromosomal translocation
events, gene amplification, and interfer-
ence with normal protein degradative
pathways. In the childhood cancer neuro-
blastoma, MYCN is highly amplified in
about 20% of cases, and these are
uniformly very aggressive neoplasms
with patients showing a poor survival
probability. Importantly, there are another
20%–30% of cases that behave in an
equally aggressive fashion but in which
the tumors do not harbor amplification of
the MYCN locus or other mechanisms for
MYCN overexpression. Strikingly, these
tumors typically overexpress MYC via
mechanisms yet to be determined (Liu
et al., 2008). While both the Aurora and
Myc gene families seem to be obvious
candidates for anticancer drug develop-
ment, the Auroras theoretically provide
a much more tractable therapeutic targetCancer Csince kinases are currently more easily
druggable, especially compared to pro-
miscuous and weak transcription factors
like Myc and N-Myc.
In this issue of Cancer Cell, Otto et al.
(2009) identify Aurora A and N-Myc as
oncogenic partners in neuroblastoma, with
Aurora A functioning to sequester N-Myc
away from ubiquitin-mediated proteolytic
degradation. Using a synthetic-lethal
screening strategy in neuroblastoma cell
line models, the investigators knocked
down 194 separate genes selected to be
candidates for allowing neural progenitor
cells to survive deregulated MYCN (forced
overexpression ofMYCN in neural progen-
itor cell models or MYCN-nonamplified
neuroblastomas results in immediate
induction of programmed cell death).
These were genes overexpressed in
MYCN-amplified tumors and/or genes
with direct evidence for being a Myc target.
AURKA was one of 17 genes that showed
selective antiproliferative effects in the
MYCN-amplified cells when the protein
was knocked down. In a series of elegant
and well-controlled experiments, Otto and
colleagues demonstrated that Aurora A
stabilizes the N-Myc protein through
a direct physical interaction and interferesell 15, January 6, 2009 ª2009 Elsevier Inc. 5
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Previewswith ubiquitin-mediated degradation in
a kinase-independent manner. The authors
caution that small-molecule inhibitors of
Aurora A kinase activity currently in devel-
opment may fail to interfere with the critical
oncogenic function of Aurora A in medi-
ating N-Myc stabilization.
Since one of the major functions of
Aurora A is to stabilize microtubular
assembly in the mitotic spindle, it perhaps
should not be too surprising that it can
also bind to and protect a critical tran-
scription factor from proteasomal degra-
dation, but this is a novel and important
observation. It will be interesting to deter-
mine whether Aurora A also stabilizes
Myc, but the data presented by Otto
et al. suggest that this is not likely, since
Myc is overexpressed in the MYCN-
nonamplified cell lines used in their exper-
iments. Regardless, the work of Otto et al.
extends an already impressive resume of
protein partners of Aurora A and further
expands its central and pleiotropic role
in cell-cycle regulation. It will be important
to understand the cellular context neces-
sary for this interaction and whether the
potential oncogenic association of these
proteins occurs only in neurally derived
cancers.
What does this mean for neuroblastoma,
especially in terms of developmental thera-
peutics? The first curious fact is that the
AURKA locus is very seldomly, if ever,
amplified in human neuroblastoma primary
tumors. We have recently screened over
600 primary neuroblastomas on a high-
density SNP array and detected amplifica-
tion in fewer than1% of cases (unpublished
data), and this is consistent with other pub-
lished comparative genomics hybridization
studies. In addition, a variety of expression6 Cancer Cell 15, January 6, 2009 ª2009 Elsprofiling studies in neuroblastoma show,as
do Otto et al., that overexpression of
AURKA is not restricted solely to MYCN-
amplified neuroblastomas. AURKA is also
highly expressed in the majority of high-
risk neuroblastomas without MYCN ampli-
fication, whereas low-risk cases, which
almost never show MYCN amplification,
generally have low expression of AURKA.
Finally, the Pediatric Preclinical Testing
Program (PPTP; http://pptp.stjude.org/)
has been performing unbiased cell line
and murine xenograft-based screens of
new drugs in development. The Aurora A
kinase inhibitor MLN8237 demonstrated
broad and unprecedented robust anti-
tumor activity inall neuroblastomasstudied
in a MYCN-independent manner (http://
pptp.stjude.org/doc/meetingPresentations/
MLN8237%20AACR%202008.pdf). In fact,
its activity in the mouse setting was
so impressive that a phase I trial in child-
ren with refractory neuroblastoma was
fast tracked and is currently enrolling
patients (http://clinicaltrials.gov/; identi-
fier NCT00739427). While the human
study will prove whether this is an active
agent for refractory neuroblastoma, the
PPTP data seem to obviate a major
concern of Otto et al., that since kinase
activity is not required for N-Myc stabiliza-
tion, kinase inhibition strategies may be
ineffective. Regardless, AURKA has
rapidly emerged as a critical oncogene in
neuroblastoma, and ongoing work will
determine whether interference with N-
Myc stabilization, inhibition of kinase-
mediated effects on cellular proliferation,
or both should be the focus of therapeutic
intervention strategies. Coupled with the
recent discovery ofALKas a mutated ther-
apeutic target in neuroblastoma (Chenevier Inc.et al., 2008; George et al., 2008; Janoueix-
Lerosey et al., 2008; Mosse et al., 2008),
investigators are now tasked with rapidly
translating these seminal advances into
thoughtfully designed clinical trials for
a disease that still exacts significant
morbidity and mortality.
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